# A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

> **NCT00451958** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 386 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix 80 mg / Degarelix 80 mg
- **DRUG:** Degarelix 160 mg / Degarelix 160 mg
- **DRUG:** Leuprolide 7.5 mg / Degarelix 80 mg
- **DRUG:** Leuprolide 7.5 mg / Degarelix 160 mg

## Key facts

- **NCT ID:** NCT00451958
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2011-10
- **Final completion:** 2011-12
- **Target enrollment:** 386 (ACTUAL)
- **Last updated:** 2013-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451958, "A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00451958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*